Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eterna Therapeutics ( (ERNA) ) has shared an announcement.
On June 2, 2025, Ernexa Therapeutics Inc. made significant amendments to its Restated Certificate of Incorporation, increasing its authorized common stock shares from 100,000,000 to 150,000,000 and allowing stockholder actions to be effected by written consent. During the 2025 Annual Meeting of Stockholders, Ernexa’s stockholders approved several proposals, including the election of directors, the ratification of Grant Thornton LLP as the independent auditor, and a reverse stock split. These changes are poised to impact the company’s operational flexibility and stakeholder engagement.
More about Eterna Therapeutics
Average Trading Volume: 222,776
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.6M
For a thorough assessment of ERNA stock, go to TipRanks’ Stock Analysis page.